AIDS. Human immunodeficiency virus (HIV) disease
Conditions
Sponsors
Vice Chancellor of Research, Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Patients must give their knowing and voluntary written consent to join the study Patients must have at least two positive ELISA HIV test results Patients who have failed to benefit from anti-retroviral drugs due to drug resistance
Exclusion criteria
Exclusion criteria: Patients with undetectable levels of blood viral content Patients with Hepatitis B or C Pregnancy and lactation Patients who have used immuno-enhancers; use of antibiotics and other prescribed medication to treat AIDS symptomology is excepted Present use of illegal drugs or alcohol Use of growth hormone 30 days prior to the study Use of testosterone or anabolic steroids 30 days prior to the study Chemotherapy, radiotherapy or interferon treatment 3 weeks prior to entering the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HIVAb. Timepoint: AT the beginning and the ending of the study. Method of measurement: HIVAb ELISA.;CBC. Timepoint: At the beginning and the ending of the study. Method of measurement: Blood Test.;Viral Load. Timepoint: Beginning and the ending of the study. Method of measurement: PCR. | — |
Secondary
| Measure | Time frame |
|---|---|
| AIDS-related clinical signs and drug interactions. Timepoint: Weekly during the course of the study. Method of measurement: Physician's examinations and phone calls in case of occurrence of sings and symptoms. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSeyed Ahmad Seyed Alinaghi, M.D.
Imam Khomeini Hospital, Tehran
Outcome results
None listed